Sanofi-Regeneron’s Dupixent approved as first treatment for AFRS

Sanofi and Regeneron won U.S. Food and Drug Administration approval on Feb. 24, 2026 for Dupixent (dupilumab) to treat allergic fungal rhinosinusitis, expanding the drug's label to patients aged 6 years and older who have a history of sino-nasal surgery. The decision makes Dupixent the first and only medicine approved specifically for AFRS, a form of chronic sinus inflammation that frequently leads to repeated operations and long-term symptoms.

AFRS is characterized by an intense immune response to fungal elements in the sinuses that produces thick allergic mucin and nasal polyps, often necessitating surgical removal to restore airflow and drainage. For many patients the disease recurs despite repeated procedures and courses of corticosteroids, creating a cycle of surgery and medical management that can span years. The FDA approval gives clinicians a targeted biological therapy option for patients who have already undergone surgery, and extends that option to pediatric patients for whom treatment choices have been more limited.

The approval has immediate clinical and public health implications. Biologic therapies such as Dupixent offer an alternative to repeated systemic steroids and additional surgery, interventions that carry risks and can strain health systems when procedures must be repeated. For families of children with recurrent AFRS, access to an approved medication could reduce surgical burden and school absences tied to chronic illness. From a population perspective, a non-surgical option may decrease procedure-related costs and post-operative complications, though the net effect will depend on uptake and coverage decisions.

Access and equity will be critical determinants of who benefits. Dupixent is a high-cost biologic, and insurers historically apply prior authorization, step therapy, and utilization management to expensive specialty drugs. Coverage policies by Medicare, Medicaid programs and private insurers will shape whether patients, particularly those in low-income or rural communities with limited specialist access, can obtain the drug. Moreover, children and adults who lack consistent specialty ENT or allergy care may face delays in diagnosis or the documentation insurers often require to approve therapy.

Clinicians and health systems will need clear protocols to integrate Dupixent into care pathways for AFRS, including defining which patients should be treated medically versus referred for repeat surgery. Public health officials should monitor real-world outcomes and disparities in access as the treatment becomes available. Data collection on reductions in surgeries, steroid exposure and school or work disruptions will be important to justify the cost and inform guideline updates.

Regulators and payers may also consider the broader implications of expanding indications for biologics into surgical diseases. As targeted therapies move into conditions traditionally managed with operations, policymakers will face questions about value, budget impact and how to ensure equitable distribution. For patients and families dealing with recurrent sinus disease, the FDA approval marks a shift toward medical options where once repeated surgery was the only path. The next challenge will be translating authorization into affordable, timely treatment across diverse communities.